Total medical devices venture financing deals in January 2019 worth $975.94m were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked an increase of 64.3% over the previous month and a rise of 31.7% when compared with the last 12-month average, which stood at $741.34m.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $682.75m. At the country level, the United States topped the list in terms of deal value at $672.71m.
In terms of volumes, North America emerged as the top region for medical devices venture financing deals globally, followed by Europe and then Asia-Pacific.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The top country in terms of venture financing deals activity in January 2019 was the United States with 54 deals, followed by China with five and Ireland with four.
Medical devices venture financing deals in January 2019: Top deals
The top five medical devices venture financing deals accounted for 34.4% of the overall value during January 2019.
The combined value of the top five medical devices venture financing deals stood at $336m, against the overall value of $975.94m recorded for the month.
The top announced medical devices venture financing deal tracked by GlobalData in January 2019 was CICC Capital ManagementLimited, IDG Capital, LB Investment, Meinian Onehealth Healthcare (Group), Ping An Insurance (Group)of China Ltd, Samsung Ventures Investment and Tasly Pharmaceutical Group’s $100m venture financing of Hangzhou KangSheng Health Management Consulting.
In second place was BioStar Ventures, Michigan Accelerator Fund I and Novus Biotechnology Fund 1’s venture financing of Ablative Solutions for $77m and in third place was Abingworth Management, Advanced Technology Ventures, Bain Capital Life Sciences, Correlation Ventures, Endeavour Vision, HBM Partners, HealthCrest, Hercules Capital and Interwest Partners’ $75m venture financing of Gynesonics.
Deerfield Management, Medical Technology Venture Partners and Seroba Life Sciences’ $45m venture financing of PQ Bypass and BlueRed Capital, Hill-Rom Holdings, Hotung Capital Management, JK&B Capital, Pitango Venture Capital, The Israel Innovation Fund, Wells Fargo Strategic Capital and ARGO Capital Partners’ venture financing of Earlysense for $39m held fourth and fifth positions, respectively.
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.